Claim(permalink)
Osimertinib (the lung cancer medication) has been licensed in the EU for use since 2016.
✓full-fact rating: not verifiable; published on 2021-05-11
Factors
veracity
not verifiable
Political Leaning
left political leaning
Sentiment
neutral sentiment
Date published
2021-05-11
Entities
MarsOsimertinibDaily ExpressEuropean CommissionMatt HancockMutationEuropean Medicines AgencySwitzerlandSingaporeBrexitSocial mediaCanadaAustraliaCancerEuropean UnionUnited KingdomBrazilFull FactSmall-cell carcinomaOrbis InternationalSubgroupNon-small-cell lung carcinoma